text Therapeutics (US:CNTX) zacks.comยท2024-05-20 17:01Company Overview - Context Therapeutics Inc. (CNTX) currently holds a Momentum Style Score of A, indicating strong momentum characteristics [2][3] - The company has a Zacks Rank of 2 (Buy), suggesting a favorable outlook compared to the market [3] Price Performance - CNTX shares have increased by 6.95% over the past week, outperforming the Zacks Medical - Drugs industry, which rose by 0.44% [5] - Over the past month, CNTX's price change is 51.51%, significantly higher than the industry's 0.74% performance [5] - In the last quarter, CNTX shares have surged by 72.41%, and over the past year, they have gained 208.17%, while the S&P 500 has only moved 6.34% and 29.26% respectively [6] Trading Volume - The average 20-day trading volume for CNTX is 1,598,397 shares, which serves as a bullish indicator when combined with rising stock prices [7] Earnings Estimates - In the past two months, one earnings estimate for CNTX has been revised upwards, while none have been lowered, leading to an increase in the consensus estimate from -$1.20 to -$0.75 [9] - For the next fiscal year, one estimate has also moved upwards with no downward revisions during the same period [9] Conclusion - Given the strong momentum indicators and positive earnings outlook, CNTX is positioned as a promising investment opportunity [10]